[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-433658-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-433658-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","outcomes-of-everolimus-treated-hrher2-breast-cancer","Outcomes of everolimus-treated HR+/HER2− breast cancer","","Editorial discussing outcomes for recurrent metastatic HR+/HER2− breast cancer treated with everolimus-based regimens in Taiwan. It summarizes a retrospective cohort of 299 patients, reporting median progression-free survival of 5.6 months and overall survival of 60.1 months, and examines effects of metastatic-free interval timing, prior chemotherapy exposure, treatment line, and recurrence sites. The editorial highlights a paradox between PFS and OS and argues for everolimus-based late-line use with individualized benefit–risk evaluation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/outcomes-of-everolimus-treated-hrher2-breast-cancer/433658/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/outcomes-of-everolimus-treated-hrher2-breast-cancer/433658.png","ImageObject",300,407,{"name":42,"@type":43},"Lucas Martin","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-29",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the purpose of the editorial about everolimus-treated HR+/HER2− breast cancer?","Question",{"text":63,"@type":64},"It reviews real-world outcomes for recurrent metastatic HR+/HER2− breast cancer patients treated with everolimus-based therapy in Taiwan and discusses clinical implications and key prognostic observations.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What survival outcomes were reported for the everolimus-treated cohort?",{"text":68,"@type":64},"The retrospective study reported a median progression-free survival of 5.6 months and a median overall survival of 60.1 months.",{"name":70,"@type":61,"acceptedAnswer":71},"Which factors were associated with prognosis in recurrent HR+/HER2− patients?",{"text":72,"@type":64},"The editorial notes that the history of prior chemotherapy and the timing/prior therapeutic lines for starting everolimus-based therapy showed positive impact, and recurrence sites such as CNS and liver were strong predictors of worse prognosis.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},433658,1790792584,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":30,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":55,"preview_page_count":4},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","J Chin MedAssoc  \nEditorial  \nOutcomes of everolimus-treated HR+/HER2− breast cancer  \nPeng-Hui Wanga,b,c,*, Szu-Ting Yanga,b, Tsung-Cheng Kuod,*  \naDepartment of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; bInstitute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC; cFemale Cancer Foundation, Taipei, Taiwan, ROC; dDepartment of Obstetrics and Gynecology, Kuo General Hospital, Tainan, Taiwan, ROC  \nBreast cancer (BC) is the most common cancer among women in Taiwan, ranking first in incidence and third in mortality.1–3 The classification of BC is usually based on histopathology (type and grade) and two key biomarkers, hormone receptors (HR, including estrogen receptor [ER] and progesterone receptor [PR]) and human epidermal growth factor receptor 2 (HER2) to establish four primary molecular subtypes, including HR-positive/ HER2-negative (HR+/HER2−), HR-negative/HER2-positive (HR−/HER2+), HR-positive/HER2-positive (HR+/HER2+), and HR-negative/HER2-negative (HR−/HER2−), also calling the aforementioned types as Luminal A, Luminal B, HER2 overexpression and triple-negative BC, remains the mainstay of current clinical practice.4–6 Among them, HR+/HER2− BC is the most common subtype, accounting for two-thirds or over of all BC patients.7 Although in theory, HR+/HER2− BC presents the most favorable histological subtype, approximately 20% of HR+/HER2− BC patients will experience recurrence and/or distant metastases within the first 10 years, and among those with potentially incurable diseases, nearly half of recurrent HR+/ HER2− BC patients ultimately die of the diseases within 4 years.7 All suggest that the clinical management of HR+/HER2− BC patients is remains unmet. We welcome the article published in the Journal of the Chinese Medical Association (JCMA), which addressed this topic. Dr. Kao et al7 reported the real-world data to show the outcomes of recurrent HR+/HER2− BC patients treated with everolimus-based regimen in Taiwan.  \nDr. Kao et al7 retrospectively enrolled 299 metastatic HR+/ HER2− BC (mHR+/HER2− BC) patients from multiple medical centers in Taiwan to evaluate the safety and therapeutic effects of everolimus-based therapy of these patients.7 The median progression-free survival (PFS) was 5.6 (95% confidence interval [CI], 4.62-6.59) months and the overall survival (OS) was 60.1 (95% CI, 52.36-67.78) months, respectively.7 The authors found that the shortening period of metastatic-free interval  \n*Address correspondence. Dr. Peng-Hui Wang, Department of Obstetricsand Gynecology, Taipei Veterans General Hospital, 201, Section 2, Shi-Pai Road, Taipei 112, Taiwan, [ROC. E-mail addresses: phwang@vghtpe.gov.tw](ROC. E-mail addresses: phwang@vghtpe.gov.tw); [pongpongwang@gmail.com](pongpongwang@gmail.com) (P.-H. Wang); Dr. Tsung-Cheng Kuo, Department of Obstetrics and Gynecology, Kuo General Hospital, 22, Section 2, Minsheng Road, Tainan 700, Taiwan, ROC. E-mail address: [tckuo@kgh.com.tw](tckuo@kgh.com.tw) (T.-C. Kuo). Conflicts of interest: Dr. Peng-Hui Wang, an editorial board member at the Journal of the Chinese Medical Association, had no role in the peer review process of or decision to publish this article. The other authors declare no conflicts of interest related to the subject matter or materials discussed in this article.  \nJournal of Chinese Medical Association. (2025) 88: 730-732.  \nReceived August 5, 2025; accepted August 6, 2025. doi: 10. 1097/JCMA.0000000000001282  \nCopyright © 2025, the Chinese Medical Association. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/](http://creativecommons.org/licenses/)[ ](http://creativecommons.org/licenses/)[by-nc-nd/4.0/](by-nc-nd/4.0/))  \n(MFI, defined recurrence occurring less than 5 years) is associated with worse prognosis (median PFS of 4.4 [95% CI, 2.80- 6.07] months), and additionally, patients with MFI ≥5 years orde novo mHR+/HER2− BC had the l","cbCaik0jXM8fWzqJ","https://ap.wps.com/l/cbCaik0jXM8fWzqJ","pdf",698332,"English","# Background and clinical need\n# Study design and key survival outcomes\n## Progression-free survival and overall survival\n# Prognostic factors and subgroup findings\n## Metastatic-free interval, prior chemotherapy, and recurrence sites\n# Interpretation and clinical implications\n## Late-line treatment and benefit–risk considerations","[{\"question\":\"What is the purpose of the editorial about everolimus-treated HR+/HER2− breast cancer?\",\"answer\":\"It reviews real-world outcomes for recurrent metastatic HR+/HER2− breast cancer patients treated with everolimus-based therapy in Taiwan and discusses clinical implications and key prognostic observations.\"},{\"question\":\"What survival outcomes were reported for the everolimus-treated cohort?\",\"answer\":\"The retrospective study reported a median progression-free survival of 5.6 months and a median overall survival of 60.1 months.\"},{\"question\":\"Which factors were associated with prognosis in recurrent HR+/HER2− patients?\",\"answer\":\"The editorial notes that the history of prior chemotherapy and the timing/prior therapeutic lines for starting everolimus-based therapy showed positive impact, and recurrence sites such as CNS and liver were strong predictors of worse prognosis.\"}]","Outcomes of everolimus-treated HR+/HER2− breast cancer | PDF",1790665013]